0001610717-23-000296.txt : 20230922 0001610717-23-000296.hdr.sgml : 20230922 20230922191250 ACCESSION NUMBER: 0001610717-23-000296 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230920 FILED AS OF DATE: 20230922 DATE AS OF CHANGE: 20230922 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ROWLAND LLOYD A CENTRAL INDEX KEY: 0001236395 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37587 FILM NUMBER: 231272755 MAIL ADDRESS: STREET 1: AMYLIN PHARMACEUTICALS INC STREET 2: 9360 TOWNE CENTRE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CytomX Therapeutics, Inc. CENTRAL INDEX KEY: 0001501989 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 273521219 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650.515.3185 MAIL ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 form4.xml X0508 4 2023-09-20 0001501989 CytomX Therapeutics, Inc. CTMX 0001236395 ROWLAND LLOYD A C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BLVD., STE. 400 SOUTH SAN FRANCISCO CA 94080 true General Counsel false Common Stock 2023-09-20 4 A 0 15000 0 A 86095 D Common Stock 2023-09-22 4 S 0 5486 1.3006 D 80609 D Represents Performance Stock Units ("PSUs") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The second milestone vesting condition was determined to be satisfied upon which the remaining 50% of the PSUs vested. Includes 41,875 restricted stock units. The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs. /s/ Lloyd Rowland 2023-09-22